IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

📊 Approval moversGordon Liu100%

Lilly Plans $2.88B Merida Autoimmune AcquisitionBusiness — Sep 3, 2026Eli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.

Lilly Retatrutide Meets Endpoints in Phase 3 Trials — Jul 23, 2026Eli Lilly announced positive Phase 3 results for retatrutide in TRIUMPH-2 and TRIUMPH-3, showing substantial weight loss and improved metabolic and cardiovascular risk markers, with average losses ranging roughly from the high 20s to the mid-50s pounds across different doses. The company plans to submit a Biologics License Application to the FDA in early 2027 as it moves toward global regulatory submissions for obesity and related conditions.